252 related articles for article (PubMed ID: 11454672)
21. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
22. DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomas.
Bredel C; Lassmann S; Pollack IF; Knoth R; Hamilton RL; Volk B; Werner M; Bredel M
Int J Oncol; 2005 May; 26(5):1187-92. PubMed ID: 15809708
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
24. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP
Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794
[TBL] [Abstract][Full Text] [Related]
25. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma.
Bozzetti C; Personeni N; Nizzoli R; Guazzi A; Flora M; Bassano C; Negri F; Martella E; Naldi N; Franciosi V; Cascinu S
Cancer; 2003 Oct; 99(5):310-5. PubMed ID: 14579298
[TBL] [Abstract][Full Text] [Related]
26. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
Kim GY; Oh YL
Cytopathology; 2004 Dec; 15(6):315-20. PubMed ID: 15606364
[TBL] [Abstract][Full Text] [Related]
27. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays.
Zhang D; Salto-Tellez M; Do E; Putti TC; Koay ES
Hum Pathol; 2003 Apr; 34(4):362-8. PubMed ID: 12733117
[TBL] [Abstract][Full Text] [Related]
29. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
30. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
[TBL] [Abstract][Full Text] [Related]
31. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
[TBL] [Abstract][Full Text] [Related]
32. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
33. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
Coss A; Tosetto M; Fox EJ; Sapetto-Rebow B; Gorman S; Kennedy BN; Lloyd AT; Hyland JM; O'Donoghue DP; Sheahan K; Leahy DT; Mulcahy HE; O'Sullivan JN
Cancer Lett; 2009 Apr; 276(2):228-38. PubMed ID: 19111388
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer.
Arriola E; Moreno A; Varela M; Serra JM; Falo C; Benito E; Escobedo AP
Eur J Cancer; 2006 Nov; 42(17):2954-60. PubMed ID: 16935488
[TBL] [Abstract][Full Text] [Related]
35. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
[TBL] [Abstract][Full Text] [Related]
36. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
37. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
38. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).
Fritzsche FR; Bode PK; Moch H; Kristiansen G; Varga Z; Bode B
Am J Surg Pathol; 2010 Aug; 34(8):1180-5. PubMed ID: 20661016
[TBL] [Abstract][Full Text] [Related]
39. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
